Why Is OLMA Stock Dropping Today? Olema Pharmaceuticals Falls After AstraZeneca Etcamah Trial Failure

Olema Pharmaceuticals (OLMA) shares fell 10. 67% in after-hours trading on Friday after AstraZeneca announced that its breast cancer drug Etcamah failed to meet the primary endpoint of a late-stage clinical trial. The setback at a direct competitor raised immediate concerns about Olema's own drug candidate in the same therapeutic class.

Why is OLMA stock dropping today? The move was triggered by negative clinical data from AstraZeneca's SERENA-4 trial, which tested Etcamah (camizestrant) — a SERD and CERAN drug that competes in the same mechanism class as Olema's lead asset palazestrant.

What Happened At AstraZeneca?

AstraZeneca announced that the SERENA-4 Phase 3 trial did not meet its primary goal of improving progression-free survival. The study tested Etcamah in combination with Pfizer's palbociclib against a standard hormone-blocking pill (anastrozole) plus palbociclib in 1,371 patients starting treatment for advanced hormone-sensitive breast cancer.

The Etcamah combination showed only a numerical improvement in progression-free survival but fell short of statistical significance. AstraZeneca said side effects were consistent with what is already known for both drugs and that it will present full results at a later date.

The setback arrived just days after the FDA granted accelerated approval to Etcamah on September 4, 2026, for a narrower patient population with ESR1 mutations. AZN shares dropped around 3% in aftermarket trading on the news. The company also has two other Phase 3 trials for Etcamah — CAMBRIA-1 and CAMBRIA-2 — examining the drug in the adjuvant setting.

Why Did The News Hit Olema?

Olema is developing palazestrant, an estrogen receptor antagonist and SERD, as a treatment for ER-positive, HER2-negative breast cancer. Because palazestrant operates in the exact same drug class as Etcamah, the negative data created a sector read-through risk.

Palazestrant is in Phase 3 development in a collaboration with Novartis as a first-line treatment in combination with the CDK 4/6 inhibitor Kisqali (ribociclib) for metastatic breast cancer. The drug is also in Phase 3 as a second- and third-line monotherapy. Top-line data from the pivotal OPERA-01 trial is expected in the first quarter of 2027.

The SERENA-4 failure does not mean palazestrant will face the same outcome — the drugs have different chemical structures and the trials enrolled distinct patient populations. Still, the result introduces uncertainty into the competitive landscape for SERD/CERAN drugs in first-line breast cancer. Investors are now weighing whether the failure reflects a broader challenge for the drug class or is specific to Etcamah's formulation and trial design.

Olema presented at Citigroup's Biopharma Back to School Summit on September 10, the day before the after-hours decline, where CEO Sean Bohen outlined the company's pipeline progress. Cash and marketable securities stood at $461.1 million as of June 30, 2026, according to earlier filings.

What Should Investors Watch Next?

The after-hours session has thinner liquidity, so the regular trading session will show whether selling pressure persists or stabilizes. Volume confirmation during open trading may indicate how deeply the AstraZeneca news has shaken investor confidence in Olema's prospects.

The next major catalyst for Olema is the OPERA-01 Phase 3 trial, with top-line data expected in Q1 2027. How the market interprets the SERENA-4 failure — as a class-wide risk or a drug-specific setback — will shape expectations heading into that readout.

AstraZeneca has not disclosed the full SERENA-4 dataset. When it does, a more complete picture of how Etcamah performed numerically may help investors assess the degree of overlap with palazestrant's trial design and patient population. Until then, the decline reflects investor caution rather than a confirmed threat to Olema's pipeline.